PRIME MEDICINE INC (PRME) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:PRME • US74168J1016

3.81 USD
+0.01 (+0.26%)
At close: Feb 3, 2026
3.73 USD
-0.08 (-2.1%)
Pre-Market: 2/4/2026, 9:20:19 AM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PRME. PRME was compared to 524 industry peers in the Biotechnology industry. While PRME has a great health rating, there are worries on its profitability. PRME is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year PRME has reported negative net income.
  • PRME had a negative operating cash flow in the past year.
  • PRME had negative earnings in each of the past 5 years.
  • PRME had a negative operating cash flow in each of the past 5 years.
PRME Yearly Net Income VS EBIT VS OCF VS FCFPRME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • PRME has a Return On Assets (-51.26%) which is comparable to the rest of the industry.
  • PRME has a Return On Equity of -121.95%. This is comparable to the rest of the industry: PRME outperforms 40.46% of its industry peers.
Industry RankSector Rank
ROA -51.26%
ROE -121.95%
ROIC N/A
ROA(3y)-69.15%
ROA(5y)-55.54%
ROE(3y)-107.23%
ROE(5y)-82.73%
ROIC(3y)N/A
ROIC(5y)N/A
PRME Yearly ROA, ROE, ROICPRME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • PRME does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRME Yearly Profit, Operating, Gross MarginsPRME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

  • PRME does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PRME has been increased compared to 1 year ago.
  • The number of shares outstanding for PRME has been increased compared to 5 years ago.
  • There is no outstanding debt for PRME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRME Yearly Shares OutstandingPRME Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
PRME Yearly Total Debt VS Total AssetsPRME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -2.33, we must say that PRME is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -2.33, PRME is in line with its industry, outperforming 49.81% of the companies in the same industry.
  • There is no outstanding debt for PRME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.33
ROIC/WACCN/A
WACC8.93%
PRME Yearly LT Debt VS Equity VS FCFPRME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • PRME has a Current Ratio of 6.61. This indicates that PRME is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 6.61, PRME is doing good in the industry, outperforming 67.18% of the companies in the same industry.
  • A Quick Ratio of 6.61 indicates that PRME has no problem at all paying its short term obligations.
  • PRME has a Quick ratio of 6.61. This is in the better half of the industry: PRME outperforms 67.94% of its industry peers.
Industry RankSector Rank
Current Ratio 6.61
Quick Ratio 6.61
PRME Yearly Current Assets VS Current LiabilitesPRME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

  • PRME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.10%, which is quite impressive.
  • PRME shows a strong growth in Revenue. In the last year, the Revenue has grown by 647.13%.
EPS 1Y (TTM)30.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.27%
Revenue 1Y (TTM)647.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%486.12%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.81% on average over the next years. This is quite good.
  • Based on estimates for the next years, PRME will show a very strong growth in Revenue. The Revenue will grow by 43.87% on average per year.
EPS Next Y19.72%
EPS Next 2Y18.87%
EPS Next 3Y13.4%
EPS Next 5Y8.81%
Revenue Next Year515.82%
Revenue Next 2Y137.29%
Revenue Next 3Y186.17%
Revenue Next 5Y43.87%

3.3 Evolution

PRME Yearly Revenue VS EstimatesPRME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
PRME Yearly EPS VS EstimatesPRME Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • PRME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRME. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRME Price Earnings VS Forward Price EarningsPRME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRME Per share dataPRME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PRME's earnings are expected to grow with 13.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.87%
EPS Next 3Y13.4%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for PRME!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PRIME MEDICINE INC

NASDAQ:PRME (2/3/2026, 8:00:00 PM)

Premarket: 3.73 -0.08 (-2.1%)

3.81

+0.01 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)02-27
Inst Owners60.72%
Inst Owner Change3.22%
Ins Owners11.36%
Ins Owner Change0%
Market Cap687.74M
Revenue(TTM)5.98M
Net Income(TTM)-197.34M
Analysts80
Price Target6.59 (72.97%)
Short Float %17.7%
Short Ratio7.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.28%
Min EPS beat(2)-24%
Max EPS beat(2)-10.55%
EPS beat(4)1
Avg EPS beat(4)-8.65%
Min EPS beat(4)-24%
Max EPS beat(4)22.47%
EPS beat(8)2
Avg EPS beat(8)-10.65%
EPS beat(12)3
Avg EPS beat(12)-8.3%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-5.06%
Min Revenue beat(2)-27.12%
Max Revenue beat(2)17%
Revenue beat(4)3
Avg Revenue beat(4)167.55%
Min Revenue beat(4)-27.12%
Max Revenue beat(4)644.42%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.4%
EPS NQ rev (1m)-1.35%
EPS NQ rev (3m)-22.7%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.7%
Revenue NQ rev (1m)1.44%
Revenue NQ rev (3m)-32.82%
Revenue NY rev (1m)-7.63%
Revenue NY rev (3m)-30.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 115.06
P/FCF N/A
P/OCF N/A
P/B 4.25
P/tB 4.25
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.03
BVpS0.9
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.26%
ROE -121.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.15%
ROA(5y)-55.54%
ROE(3y)-107.23%
ROE(5y)-82.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.22%
Cap/Sales 100.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.61
Quick Ratio 6.61
Altman-Z -2.33
F-Score6
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)343.92%
Cap/Depr(5y)671.96%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.27%
EPS Next Y19.72%
EPS Next 2Y18.87%
EPS Next 3Y13.4%
EPS Next 5Y8.81%
Revenue 1Y (TTM)647.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%486.12%
Revenue Next Year515.82%
Revenue Next 2Y137.29%
Revenue Next 3Y186.17%
Revenue Next 5Y43.87%
EBIT growth 1Y9.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.34%
EBIT Next 3Y5.34%
EBIT Next 5YN/A
FCF growth 1Y29.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.38%
OCF growth 3YN/A
OCF growth 5YN/A

PRIME MEDICINE INC / PRME FAQ

What is the fundamental rating for PRME stock?

ChartMill assigns a fundamental rating of 3 / 10 to PRME.


What is the valuation status of PRIME MEDICINE INC (PRME) stock?

ChartMill assigns a valuation rating of 0 / 10 to PRIME MEDICINE INC (PRME). This can be considered as Overvalued.


What is the profitability of PRME stock?

PRIME MEDICINE INC (PRME) has a profitability rating of 1 / 10.


What is the earnings growth outlook for PRIME MEDICINE INC?

The Earnings per Share (EPS) of PRIME MEDICINE INC (PRME) is expected to grow by 19.72% in the next year.